Literature DB >> 19752878

Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C.

M-H Hsieh1, C-K Ho, N-J Hou, M-Y Hsieh, W-Y Lin, J-F Yang, C-C Chiu, J-F Huang, N-C Chang, C-L Wang, C-Y Dai, W-L Chuang, M-L Yu.   

Abstract

BACKGROUND: Metabolic syndrome (MS) is considered a cause of abnormal deposition of fat into hepatocytes, which might be associated with hepatic steatosis or abnormal liver function.
OBJECTIVE: The aim of this study was to explore the factors associated with MS and the relationship between MS and abnormal aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) levels in Taiwanese subjects without chronic hepatitis B (CHB) or C (CHC).
SUBJECTS: We enrolled 2539 Taiwanese adults without CHB or CHC (age range: 16-88 years old) and investigated the factors related to MS using the NCEP-ATP (National Cholesterol Education Program-Adult Treatment Panel) III criteria; body mass index (BMI) was measured using Asia-Pacific criteria.
RESULTS: The prevalence rate of MS in Taiwanese adults without CHB or CHC was 16.9% using the modified ATP III criteria and 15.4% using the International Diabetes Federation criteria. Males had a significantly higher prevalence rate than females (P<0.001), and subjects with MS were significantly older and had significantly higher BMI values and AST, ALT and GGT levels (all P<0.001). In univariate analyses, the abnormality of liver function test results were related to gender, level of fasting sugar, systolic blood pressure, triglyceride, high-density lipoprotein, BMI and MS (all P<0.05). Multivariate analysis showed that the male gender, a higher BMI value and MS were related to abnormal liver function test results. The cutoff value for ALT in relation to MS is 31 IU l(-1) for male and 18 IU l(-1) for female.
CONCLUSION: The prevalence of MS in Taiwanese adults without hepatitis B or C was found to be high, and MS and BMI were identified as being related to abnormal liver function test results in these adults.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19752878     DOI: 10.1038/ijo.2009.172

Source DB:  PubMed          Journal:  Int J Obes (Lond)        ISSN: 0307-0565            Impact factor:   5.095


  12 in total

1.  Erosive esophagitis associated with metabolic syndrome, impaired liver function, and dyslipidemia.

Authors:  Song-Seng Loke; Kuender D Yang; Kuang-Den Chen; Jung-Fu Chen
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

2.  Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study.

Authors:  Stacy A Porter; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Caroline S Fox
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

3.  Inflammation and biochemical features of bariatric candidates: does gender matter?

Authors:  Alvaro A C Morais; Joel Faintuch; Ana A D Leal; Joao A B Noe; Diandria M Bertollo; Rafael C Morais; Daniele Cabrini
Journal:  Obes Surg       Date:  2010-02-02       Impact factor: 4.129

4.  Circulating alanine transaminase (ALT) and γ-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study.

Authors:  Xiaowen Liu; Ole-Petter R Hamnvik; John P Chamberland; Michael Petrou; Huizhi Gong; Costas A Christophi; David C Christiani; Stefanos N Kales; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-03-15       Impact factor: 8.694

5.  Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome.

Authors:  Shaohang Cai; Zejin Ou; Duan Liu; Lili Liu; Ying Liu; Xiaolu Wu; Tao Yu; Jie Peng
Journal:  United European Gastroenterol J       Date:  2018-01-16       Impact factor: 4.623

6.  Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes.

Authors:  Lucivalda Pereira Magalhães Oliveira; Rosangela P de Jesus; Ramona S S B Boulhosa; Carlos Mauricio C Mendes; Andre Castro Lyra; Luiz Guilherme C Lyra
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

7.  Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients.

Authors:  Chi-Ming Tai; Chih-Kun Huang; Hung-Pin Tu; Jau-Chung Hwang; Ming-Lun Yeh; Chung-Feng Huang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

8.  Association between liver function and metabolic syndrome in Chinese men and women.

Authors:  Sen Wang; Jie Zhang; Li Zhu; Linlin Song; Zhaowei Meng; Qiang Jia; Xue Li; Na Liu; Tianpeng Hu; Pingping Zhou; Qing Zhang; Li Liu; Kun Song; Qiyu Jia
Journal:  Sci Rep       Date:  2017-03-20       Impact factor: 4.379

9.  Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels.

Authors:  Eun Young Park; Min Kyung Lim; Jin-Kyoung Oh; Heeyoun Cho; Mi Jin Bae; E Hwa Yun; Dong-il Kim; Hai-Rim Shin
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

Review 10.  Nonalcoholic fatty liver disease: Diagnostic biomarkers.

Authors:  Fatemeh Hadizadeh; Elham Faghihimani; Peyman Adibi
Journal:  World J Gastrointest Pathophysiol       Date:  2017-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.